Insider Transactions in Q1 2024 at Catalyst Pharmaceuticals, Inc. (CPRX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 27
2024
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Open market or private sale
|
Direct |
25,000
-16.73%
|
$400,000
$16.44 P/Share
|
|
Feb 15
2024
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,353
-1.55%
|
-
|
|
Feb 15
2024
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,667
+5.99%
|
-
|
|
Feb 15
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,435
-4.52%
|
-
|
|
Feb 15
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+15.67%
|
-
|
|
Feb 15
2024
|
Molly Harper Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+42.86%
|
-
|
|
Feb 15
2024
|
Preethi Sundaram Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,025
-19.09%
|
-
|
|
Feb 15
2024
|
Preethi Sundaram Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,667
+34.56%
|
-
|
|
Feb 15
2024
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,667
+1.63%
|
-
|
|
Feb 15
2024
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+0.58%
|
-
|
|
Feb 15
2024
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+1.13%
|
-
|
|
Feb 15
2024
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+0.9%
|
-
|
|
Feb 15
2024
|
Richard J Daly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,186
-0.56%
|
-
|
|
Feb 15
2024
|
Richard J Daly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+1.84%
|
-
|
|
Feb 15
2024
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,125
-10.74%
|
-
|
|
Feb 15
2024
|
Jeffrey Del Carmen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,667
+26.83%
|
-
|
|
Feb 05
2024
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+8.43%
|
$160,000
$4.01 P/Share
|
|
Jan 30
2024
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
143,000
+1.55%
|
-
|
|
Jan 02
2024
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+8.09%
|
$60,000
$1.13 P/Share
|
|
Jan 02
2024
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.82%
|
$10,000
$1.13 P/Share
|
|
Jan 02
2024
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
250,000
+5.39%
|
$250,000
$1.13 P/Share
|